Roche’s Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients…
Roche’s Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients…